Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.71 |
| ▸ | PRKCA | P17252 | 6/20 | 0.51 |
| ▸ | DGKA | P23743 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3189683 | 1.00 | NAAA (0.71) | NAAAPRKCADGKALMNA | |
| SCHEMBL15166941 | 0.98 | NAAA (0.72) | NAAAPRKCADGKALMNA | |
| SCHEMBL9861642 | 0.98 | NAAA (0.74) | NAAAPRKCADGKALMNA | |
| SCHEMBL28446717 | 0.98 | NAAA (0.74) | NAAAPRKCADGKALMNA | |
| SCHEMBL3171692 | 0.98 | NAAA (0.74) | NAAAPRKCADGKALMNA | |
| SCHEMBL9861650 | 0.98 | NAAA (0.74) | NAAAPRKCADGKALMNA | |
| SCHEMBL3179072 | 0.98 | NAAA (0.74) | NAAAPRKCADGKALMNA | |
| SCHEMBL3179079 | 0.98 | NAAA (0.74) | NAAAPRKCADGKALMNA | |
| SCHEMBL9861645 | 0.98 | NAAA (0.74) | NAAAPRKCADGKALMNA | |
| SCHEMBL28445763 | 0.98 | NAAA (0.74) | NAAAPRKCADGKALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420853-B2 | Derivatives of cyclic compound and the use thereof | Wonkisopharm Co., Ltd (KR) | 2013-04-16 | — | — | US | claimed |
| WO-2008004788-A1 | NOVEL DERIVATIVES OF CYCLIC COMPOUND AND THE USE THEREOF | WONKISOPHARM CO., LTD. (KR) | 2008-01-10 | — | — | WO | claimed |
| CN-106309421-B | Pharmaceutical composition and cosmetic composition | 沃凯索法株式会社 | 2020-08-25 | — | — | CN | disclosed |
| US-8420853-B2 | Derivatives of cyclic compound and the use thereof | Wonkisopharm Co., Ltd (KR) | 2013-04-16 | — | — | US | disclosed |
| US-20100022461-A1 | Novel Derivatives of Cyclic Compound And The Use Thereof | WONKISOPHARM CO., LTD. (KR) | 2010-01-28 | — | — | US | disclosed |
| WO-2008004788-A1 | NOVEL DERIVATIVES OF CYCLIC COMPOUND AND THE USE THEREOF | WONKISOPHARM CO., LTD. (KR) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022461-A1 | Novel Derivatives of Cyclic Compound And The Use Thereof | TYR, MC1R, PDE7A | NAAA 3623/4885PRKCA 246/4885DGKA 3090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.